Clinical characteristics, management and outcomes in immune checkpoint inhibitor-induced central nervous system demyelinating disease

During Immune Checkpoint Inhibitor Therapy: Epidemiology, Clinical

Triple-M syndrome after immune checkpoint inhibitors: a systematic review of cases—early recognition is critical to survival

Introduction Immune checkpoint inhibitors have markedly improved outcomes in advanced malignancies by enhancing antitumor immunity, but they may also disrupt immune tolerance and induce immune-related adverse events involving multiple organs; among these, the overlap of myositis, myocarditis, and Myasthenia Gravis (tri...

Immune-mediated liver injury caused by checkpoint inhibitors: A case series and review of the literature.

Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 agents, exhibit notable efficacy across various types of cancer. Nevertheless, they can trigger immune-related adverse events, among which immune-mediated liver injury (ILICI) occurs in 5-10% of patients. Corticosteroids are currently recommended...

Immune checkpoint inhibitors-related cytokine storm syndrome: a systematic review of characteristics, treatment, and outcomes

CRS induced by ICIs is a rare but severe irAE, and individualized treatment should be implemented as early as possible to ensure the safe administration of ICIs.

Systemic Sclerosis Induced by Immune Checkpoint Inhibitors from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO): A Case Series

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, improving outcomes in multiple advanced malignancies. Their use is often limited by immune-related adverse events (irAEs), including rare rheumatic irAEs, such as ICI-induced systemic sclerosis (ICI-SSc). Compared to idiopathic SSc, ICI-SSc typ...

Immune Checkpoint Inhibitors in Cancer Patients with Pre-existing Autoimmune Disease: Comparative Safety and Efficacy in a Registered Systematic Review.

BACKGROUND This study aimed to compare the safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with and without pre-existing autoimmune disease (AID). METHODS We conducted a registered systematic review with a restricted meta-analysis. PubMed, EMBASE, and the Cochrane Library were searched for publ...